DUBLIN, Aug. 29, 2022 /PRNewswire/ — The “Medical Device Reprocessing Market by Type (Reprocessed Medical Devices), Device Category (Critical- Devices, Semi-Critical Devices, Non-Critical Devices), Application (Cardiology, Gynecology, Gastroenterology, Anesthesia) – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The medical device reprocessing market is projected to reach USD 3.9 billion by 2027 from USD 2.0 billion in 2022, at a CAGR of 13.7% during the forecast period.
Growth in the market is mainly driven by the growing need to minimize hospital costs and the rising geriatric population, and the favourable regulatory approvals for reuse of single-use reprocessed medical devices. However, the requirement to follow stringent regulatory procedures to enter the medical device reprocessing market may pose a threat to the market growth.
Based on type, the reprocessing support & services segment holds the largest market share in 2021
Based on type, the medical device reprocessing market is segmented into reprocessing support & services and reprocessed medical devices. In 2021, the reprocessing support & services segment accounted for the largest share of this market, primarily due to the growing need implement strategies to reduce medical wastes.
Based on device type , critical devices segment accounted for the largest share of the medical device reprocessing market
Based on the device type, the medical device reprocessing market is segmented into critical devices, semi-critical devices, and non-critical devices. In 2021, the critical devices segment accounted for the largest share of this market. The growth of this segment is mainly attributed to the increased utilization of reprocessed medical devices for cardiac surgeries and electrophysiology procedures.
Based on application, cardiology segment is expected to have the highest CAGR during the forecast period
Based on application, the medical device reprocessing market is segmented into cardiology, gastroenterology, gynecology, arthroscopy and orthopedic surgery, general surgery & anesthesia, and other applications (urology, non-invasive surgeries, and patient monitoring). The cardiology segment is expected to register the highest growth during the forecast period. This can be attributed to the increasing prevalence of cardiovascular diseases as well as the increasing number of cardiac procedures, which utilizes a large volume of reprocessed cardiology catheters and other equipments.
North America accounted for the largest share of the medical device reprocessing market in 2021
North America accounted for the largest share of the medical device reprocessing market in 2021. Factors such as the increasing need to reduce the healthcare costs in US, and the presence of top medical device reprocessing service providers in the US region are expected to contribute to the growth of the medical device reprocessing market in North America.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Brief Overview of Medical Device Reprocessing Market
4.2 Asia-Pacific: Medical Device Reprocessing Market, by Device Type and Country (2021)
4.3 Medical Device Reprocessing Market: Geographic Growth Opportunities
4.4 Medical Device Reprocessing Market, by Region (2020-2027)
4.5 Medical Device Reprocessing Market: Developed Vs. Developing Markets
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Level of Supply Chain Cost Savings in Healthcare Facilities
5.2.1.2 Growing Adoption of Strategies for Sustainability and Environmental Safety
5.2.1.3 Rising Geriatric Population
5.2.2 Restraints
5.2.2.1 Increasing Risk of Hospital-Acquired Infections Among Patients
5.2.2.2 Increasing Number of Medical Device Surface Alterations Due to Reprocessing
5.2.3 Opportunities
5.2.3.1 Regulatory Changes Favoring Adoption of Medical Device Reprocessing
5.2.3.2 Growing Opportunities and Favorable Regulations in Developing Countries
5.2.4 Challenges
5.2.4.1 Stringent Regulatory Procedures for Reprocessed Medical Devices
5.3 Key Conferences and Events
5.4 Industry Trends
5.4.1 Expanding Service Portfolio and Market Reach Through Acquisitions
5.4.2 Specialty Reprocessing
5.5 Porter’s Five Forces Analysis
5.6 Regulatory Bodies, Government Agencies, and Other Organizations
5.7 Regulatory Analysis
5.7.1 North America
5.7.1.1 US
5.7.1.2 Canada
5.7.2 Europe
5.7.3 Asia-Pacific
5.7.3.1 Japan
5.7.3.2 Australia
5.7.3.3 Rest of Asia-Pacific
5.8 Technology Analysis
5.9 Supply Chain Analysis
5.10 Ecosystem Analysis
5.11 Medical Device Reprocessing Market: Patent Analysis
5.11.1 Patent Publication Trends for Medical Device Reprocessing
5.11.2 Insights: Jurisdiction and Top Applicant Analysis
5.12 Impact of COVID-19 on Medical Device Reprocessing Market
6 Medical Device Reprocessing Market, by Type
6.1 Introduction
6.2 Reprocessing Support and Services
6.2.1 Reducing In-House Reprocessing Costs and Increasing Regulatory Mandates to Drive Market
6.3 Reprocessed Medical Devices
6.3.1 Increasing Adoption of Reprocessed Devices at Lower Costs to Drive Market
7 Medical Device Reprocessing Market, by Device Type
7.1 Introduction
7.2 Critical Devices
7.2.1 High Cost of Buying New Devices to Drive Market
7.3 Semi-Critical Devices
7.3.1 Increased Cases of Hospital-Acquired Infections to Drive Market
7.4 Non-Critical Devices
7.4.1 Increasing Medical Procedures and Surgeries to Drive Market
8 Medical Device Reprocessing Market, by Application
8.1 Introduction
8.2 Cardiology
8.2.1 Rising Coronary Artery Disease Cases to Propel Market
8.3 Gastroenterology
8.3.1 Increasing Use of Endoscopes for Disease Diagnosis to Drive Market
8.4 Arthroscopy and Orthopedic Surgery
8.4.1 Regulatory Initiatives and Cost Reduction to Drive Market
8.5 Gynecology
8.5.1 Increasing Gynecology Procedures to Drive Market
8.6 General Surgery
8.6.1 Low-Cost General Surgery Devices to Impact Market
8.7 Other Applications
9 Medical Device Reprocessing Market, by Region
10 Competitive Landscape
10.1 Overview
10.2 Key Player Strategies/Right to Win
10.2.1 Overview of Strategies Adopted by Players in Medical Device Reprocessing Market
10.3 Revenue Share Analysis of Key Players
10.4 Market Share Analysis, 2021
10.5 Competitive Benchmarking
10.6 Company Footprint
10.7 Company Evaluation Quadrant
10.7.1 Stars
10.7.2 Emerging Leaders
10.7.3 Pervasive Players
10.7.4 Participants
10.8 Competitive Scenario
10.8.1 Fda Approvals/Service Enhancements
10.8.2 Deals
10.8.3 Other Developments
11 Company Profiles
11.1 Key Players
11.1.1 Stryker Corporation
11.1.2 Johnson & Johnson
11.1.3 Medtronic plc
11.1.4 Steris Healthcare
11.1.5 Cardinal Health (Sustainable Technologies)
11.1.6 Arjo Group (Renu Medical, Inc.)
11.1.7 Vanguard Ag
11.1.8 Medline Renewal
11.1.9 Innovative Health
11.1.10 Steripro Canada, Inc
11.1.11 Northeast Scientific, Inc.
11.2 Other Players
11.2.1 Suretek Medical
11.2.2 Konoike Group
11.2.3 Avante Health Solutions
11.2.4 Medsalv
11.2.5 Vitruvia Medical Ag
12 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/tri53o
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/the-worldwide-medical-device-reprocessing-industry-is-expected-to-reach-3-9-billion-by-2027–301613660.html
SOURCE Research and Markets
Yahoo Finance Live anchors discuss why Bristol-Myers Squibb stock is down today.
Blood thinners produced by drug giants Bristol Myers and Bayer fell short of predictions, leading shares of both stocks down Monday.
(Bloomberg) — Few outside of India had heard of Gautam Adani just a few years ago. Now the Indian businessman, a college dropout who first tried his luck as a diamond trader before turning to coal, has become the world’s third-richest person. Most Read from BloombergDOJ Response Raises Doubts on Trump ‘Special Master’ RequestPowell Heaps Pressure on Risk Sentiment as More Catalysts Loom‘Inflation Fever’ Is Finally Breaking — But Central Banks Won’t Stop Hiking RatesTrademark Filings Suggest App
Shares of Apple topped around $175 in the middle of August and turned lower – we hope traders took appropriate action. The trading volume does not appear to have increased on the late August decline but the On-Balance-Volume (OBV) line is pointing lower. In this weekly Japanese candlestick chart of AAPL, below, we can see a top reversal pattern in August looking at the candles.
Moscow is raking in more revenue than ever with the help of new buyers, new traders and the world’s seemingly insatiable demand for crude. “Nobody’s brave enough to embargo 7.5 million barrels a day of Russian oil and oil products.”
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN). Cemdisiran is an investigational RNAi therapeutic targeting the C5 component of the complement pathway and is under development in collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). New results demonstrated a 36% reduction in 24-hour urine total protein and a higher proportion, 32% versus 13%, of patients treated with cemdisiran as compared to tho
Is Pfizer stock a sell on an expected decline for Covid vaccine sales in the third quarter? Is PFE stock now a sell?
Monkeypox cases could be coming down, but the CDC is still seeing a concerning rise in much of the U.S.
Body acceptance with a healthy dose of humor.
When it comes to investing greats, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett deserves to be in a class of his own. Although no investor is infallible, Warren Buffett's incredible track record speaks for itself. It's why everyone from Wall Street professionals to everyday investors waits on the edge of their seats to find out what the Oracle of Omaha has been buying, selling, and holding.
Three steel stocks have formed valid bases and are in or near buy zones. However, views conflict on the steel market.
Medications can cause a wide range of side effects—some unpleasant and others downright dangerous. "One of the more dangerous side effects which is often overlooked is forgetfulness," says David Cutler, MD, a family medicine physician at Providence Saint John's Health Center in Santa Monica, California. "One of the reasons forgetfulness may be overlooked is that forgetfulness from treatment can often not be differentiated from forgetfulness from the underlying disease," he tells Best Life. For s
Bristol-Myers Squibb Co (NYSE: BMY) and Johnson & Johnson's (NYSE: JNJ) Janssen announced results from the Phase 2 AXIOMATIC-SSP dose-ranging study of the investigational oral factor XIa (FXIa) inhibitor, milvexian. The data showed that milvexian failed its primary endpoint, a composite endpoint measuring both the dose-response compared with placebo in stroke incidence and a biomarker known as brain infarctions, or lesions that may appear in the absence of a stroke. Also See: Bristol-Myers Squib
MELBOURNE (Reuters) -Woodside Energy Group Ltd more than tripled its interim dividend payout on Tuesday after the Australian gas producer posted a five-fold increase in first-half profit on booming oil and gas prices and its takeover of BHP Group's petroleum arm. Woodside has benefited from soaring liquefied natural gas (LNG) prices as sanctions on Russia after its invasion of Ukraine have forced gas buyers from Asia and Europe to seek alternative suppliers in what was already a tight market. "We're in uncharted waters," Chief Executive Meg O'Neill told Reuters, pointing to the Platts JKM benchmark price assessment rocketing to $71 per million British thermal units and the Dutch TTF gas hub price last week hitting roughly the equivalent of an oil price of $600 a barrel.
Tesla's CEO has been sounding the alarm on the importance of the Russian war in Ukraine for the world.
KPIX 5's Amanda Starrantino chats with Dr. Neha Narula from Stanford Health Care about the long-term covid effects and how the covid boosters targeting the Omicron variant will be available soon.
We all know there's no magic pills to keep us healthy and we've got to put in the work with good food and exercise to have optimal health. Getting the nutrients we need is essential for our well-being and if you have a balanced diet chances are you don't need supplements. However, there are cases when they're necessary like vitamin deficiencies and there's no shortage of options. While the shelves are lined with products promising health benefits, there's little to no value with many. Eat This,
Yahoo Finance reporter Pras Subramanian discusses Honda and LG teaming up for a new EV battery plant and how more and more companies are investing billions in these plants across the U.S.
The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week that target the latest versions of the omicron variant but will do so without data from a study showing the shots were safe and worked in humans.
If it was publicly traded, Berkshire Hathaway Energy would be the second-biggest U.S. utility. Earnings have grown 30-fold since Buffett bought the core of the business in 2000.

source